Brighter’s main Actiste patent granted in India – can support the growing biosimilar industry
Brighter's main patent for Actiste® has been granted in India, a front-running market in the biosimilar industry. “India’s growing biosimilars landscape, a USD multi-billion market addressing the pressing global need for more cost-efficient drugs, creates an opportunity for Brighter to support pharmaceutical companies in their drug development by providing highly valuable data related to e.g. drug efficiency,” says Henrik Norström, Brighter’s CEO. Biosimilars presents a $240 Billion global opportunity for Indian Pharmaceuticals Industry while domestic market is expected to cross $40